摘要
目的:评估鼻内联合应用鼻用抗组胺药氮卓斯汀鼻喷剂(AZENS)和鼻用激素丙酸氟替卡松鼻喷剂(FPNS)改善持续性非变应性鼻炎(NAR)鼻塞症状的有效性。方法:162例持续性NAR患者随机分为联合治疗组(AZENS+FPNS)和鼻用激素组(FPNS),比较2组患者在治疗前、治疗2周及6周时鼻塞症状的评分,并对治疗方案(包括方便性、不良反应、费用、疗效)进行总的满意度评价。结果:2组患者的鼻塞症状在治疗前、治疗2周和6周的3次评分均呈现逐次下降趋势,差异均有统计学意义(P<0.01);在治疗2周和6周时,联合治疗组患者鼻塞症状的改善明显优于鼻用激素组,差异均有统计学意义(P<0.01)。联合治疗组患者对治疗方案总的满意度评价优于鼻用激素组(P<0.05)。结论:鼻内联合用药能更快速有效地改善持续性NAR的鼻塞症状,同时具有良好的安全性和耐受性。
Objective： To determine if greater efficacy could be achieved with the intranasal antihistamine azelastine and the intranasal corticosteroid fluticasone propionate used concurrently in the treatment of nasal ob- struction of persistent non-allergic rhinitis. Method： A total of 162 persistent non-allergic rhinitis cases with mod- erate to severe nasal obstruction were randomized to treatment with the following： the combination therapy or na- sal corticosteroids monotherapy. Efficacy was assessed by change from baseline in nasal obstruction score at week 2 and week 6 visits. The perceptions of global treatment satisfaction（convenience, side effects, cost and effective- ness） in both groups were analyzed. Result：In both groups, the nasal obstruction score assessment descended sig- nificantly at week 2 and week 6 visits versus at baseline （all P〈0.01）. At week 2 and week 6 visits, the nasal ob- struction score in the combination therapy groups were significantly improved than that in nasal corticosteroids monotherapy groups （all P〈0.01）. The perceptions of global treatment satisfaction in the combination therapy groups were significantly better （P〈0.05）. Conclusion：Azelastine nasal spray and intranasal corticosteroid in com- bination may provide a substantial therapeutic benefit for patients with persistent non-allergic rhinitis, especially nasal obstruction. The combination therapy was well tolerated and safety.
出处
《临床耳鼻咽喉头颈外科杂志》
CAS
北大核心
2015年第3期243-245,251,共4页
Journal of Clinical Otorhinolaryngology Head And Neck Surgery
关键词
持续性非变应性鼻炎
抗组按药物
鼻用激素
鼻塞
persistent non-allergic rhinitis
azelastine nasal spray
nasal corticosteroids
nasal obstruction
